SCHEMBL7222252

SCHEMBL7222252

CCCCN(CC)c1cc(C)nc2c1c1ccccc1n2-c1c(C)cc(C)cc1C

nearest known ligand 0.69

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 18/20 0.69
TDP1 Q9NUW8 2/20 0.50
FPR3 P25089 2/20 0.44
TSPO P30536 2/20 0.44
TMEM97 Q5BJF2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7215931 0.89 CRHR1 (0.57) CRHR1TDP1
SCHEMBL7222478 0.82 CRHR1 (0.55) CRHR1
SCHEMBL8617375 0.82 CRHR1 (1.00) CRHR1TDP1FPR3TSPOTMEM97
SCHEMBL7215696 0.78 CRHR1 (0.69) CRHR1TDP1FPR3TSPOTMEM97
SCHEMBL7676276 0.77 CRHR1 (0.49) CRHR1
SCHEMBL5599498 0.75 CRHR1 (0.72) CRHR1TDP1FPR3TSPOTMEM97
SCHEMBL7684798 0.75 CRHR1 (0.51) CRHR1
SCHEMBL226802 0.74 CRHR1 (0.77) CRHR1TDP1FPR3TSPOTMEM97
SCHEMBL8062659 0.74 CRHR1 (0.42) CRHR1
SCHEMBL7677531 0.74 CRHR1 (0.53) CRHR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020111490-A1 Certain pyrrolopyridine derivatives: novel CRF1 specific ligands NEUROGEN CORPORATION (US) 2002-08-15 US claimed
US-6355651-B1 AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS NEUROGEN CORPORATION 2002-03-12 US claimed
US-5955613-A Certain pyrrolopyridine derivatives; novel CRF1 specific ligands NEUROGEN CORPORATION (US) 1999-09-21 US claimed
WO-1998045295-A1 CERTAIN PYRROLOPYRIDINE DERIVATIVES; NOVEL CRF1 SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1998-10-15 WO claimed
US-6670371-B2 Antagonists of Corticotropin-Releasing Factor NEUROGEN CORPORATION 2003-12-30 US disclosed
US-20020111490-A1 Certain pyrrolopyridine derivatives: novel CRF1 specific ligands NEUROGEN CORPORATION (US) 2002-08-15 US disclosed
US-6355651-B1 AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS NEUROGEN CORPORATION 2002-03-12 US disclosed
US-6133282-A Certain pyrrolopyridine derivatives; novel CRF1 specific ligands NEUROGEN CORPORATION (US) 2000-10-17 US disclosed
US-5955613-A Certain pyrrolopyridine derivatives; novel CRF1 specific ligands NEUROGEN CORPORATION (US) 1999-09-21 US disclosed
WO-1998045295-A1 CERTAIN PYRROLOPYRIDINE DERIVATIVES; NOVEL CRF1 SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111490-A1 Certain pyrrolopyridine derivatives: novel CRF1 specific ligands CRHR1, CRH, CRHR2 CRHR1 1/4885TDP1 2064/4885FPR3 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.